Dr. Nazia Chaudhary - Cancer research- therapy resistance - Best Researcher Award

ACTREC,TMC - India

Author Profile

🧪 Early academic pursuits

Chaudhary s. nazia's academic journey began with an intense passion for microbiology, which led her to achieve a stellar 80% in her bachelor’s degree from sophia college, university of mumbai, in 2013. she further pursued a master’s degree in microbiology at st. xavier’s college, where she graduated with distinction, securing 73.5% in 2015. her academic foundation set the stage for a doctoral pursuit at the advanced centre for treatment, research, and education in cancer (actrec), where she completed her phd in march 2022. her research explored the intricate mechanisms that promote tumorigenesis and resistance to radio- and chemotherapy.

🧬 Professional endeavors

Nazia embarked on a remarkable career as a dst inspire faculty at actrec-tata memorial centre (tmc). her dedication to understanding cancer biology has been a cornerstone of her professional work. through rigorous experimentation and innovative approaches, she has consistently contributed to advancing research in oncology. her faculty position at actrec underscores her commitment to fostering new scientific breakthroughs and mentoring future researchers in the field.

🔬 Contributions and research focus

Nazia’s research revolves around understanding cancer mechanisms at the molecular level. her phd project provided groundbreaking insights into the pathways that promote tumorigenesis and resistance to treatment in the absence of plakophilin 3. her earlier work includes projects on thermophiles from ganeshpuri hot springs, Cancer research- therapy resistance mitochondrial function regulation, and industrially important thermophilic actinomycetes. her innovative studies highlight her ability to blend fundamental microbiological concepts with cutting-edge biomedical applications.

🏆 Accolades and recognition

Nazia’s groundbreaking research has been recognized through prestigious patents. she is a co-inventor of two patents focused on antibodies against lipocalin-2 and Cancer research- therapy resistance their therapeutic applications. these patents signify her impactful contributions to cancer treatment strategies and her recognition as a key innovator in her field.

🌍 Impact and influence

Nazia’s work has influenced the scientific community by providing deeper insights into tumor biology and therapeutic resistance. her contributions to understanding Cancer research- therapy resistance mitochondrial regulation and cancer pathways have added valuable knowledge to the field of molecular oncology. as a dst inspire faculty, she continues to inspire and guide young researchers, amplifying her influence in shaping the next generation of scientists.

🌟 Legacy and future contributions

With her focus on uncovering novel therapeutic targets and mechanisms in oncology, nazia aims to create a legacy of impactful research that bridges fundamental science and clinical applications. her continued efforts in cancer research promise to deliver innovative solutions that could transform patient care and improve outcomes for those affected by the disease. her dedication to mentorship ensures her knowledge and passion will resonate through the researchers she inspires.

Notable Publications

Title: LCN2 promotes focal adhesion formation and invasion by stimulating Src activation
Author(s): Bhagya Shree Choudhary; Nazia Chaudhary; Aditi Vijan; Dibita Mandal; Leena Pilankar; Shubham Gawand; Bushra K. Khan; Anusha Shivashankar; Rinki Doloi; Neha Joshi et al.
Journal: Preprint
Title: EGFR-to-Src family tyrosine kinase switching in proliferating-DTP TNBC cells creates a hyperphosphorylation-dependent vulnerability to EGFR TKI
Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Anusha Shivashankar; Subhakankha Manna; Khyati Ved; Shagufa Shaikh; Sonal Khanna; Jeetnet Barr; Jagruti Dani; Nandini Verma
Journal: Preprint
Title: GPX4-VIM equates a proliferating DTP state in TNBC subtypes with converged vulnerabilities to autophagy and glutathione inhibition
Author(s): Nazia Chaudhary; Bhagya Shree Choudhary; Sushmita Patra; Shivani Malvankar; Anusha Shivashankar; Eeshrita Jog; Vaishali V. Kailje; Sonal Khanna; Subhakankha Manna; Sarthak Sahoo et al.
Journal: Preprint
Title: Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration
Author(s): Choudhary BS; Chaudhary N; Shah M; Dwivedi N; P K S; Das M; Dalal SN
Journal: FEBS Letters
Title: The Role of Lipocalin 2 (LCN2) in Regulating Ferroptosis and Therapy Resistance
Author(s): Rinki Doloi; Nazia Chaudhary; Sorab N. Dalal
Journal: National Research Scholars' Meet 2021 - Abstracts

🎓 Early academic pursuits

Melania Tesio embarked on her academic journey with a solid foundation in medical biotechnology, earning her degree with full honors from the university of torino, italy, in 2002. her passion for oncology led her to pursue a doctoral degree, culminating in a ph.d. in human oncology in 2007. her studies were uniquely enriched by a dual affiliation with the university of torino and the weizmann institute of science, israel, where she collaborated on groundbreaking research projects that laid the groundwork for her future contributions to cancer research.

🧪 Professional endeavors

Following her ph.d., Melania transitioned into impactful research roles. from 2007 to 2008, she worked as a postdoctoral researcher at the weizmann institute of science under prof. tsvee lapidot, where she delved into hematopoietic and immune system dynamics. subsequently, she joined the german cancer research center (dkfz) in 2008, collaborating with prof. andreas trumpp until 2014. since 2017, she has been a researcher at inserm, contributing significantly to unit u1111, lyon, france, where she focuses on translational cancer research while balancing her roles during maternity leave and part-time work.

🔬 Contributions and research focus

Melania's research has consistently centered on understanding the molecular mechanisms underpinning cancer, particularly t-cell acute lymphoblastic leukemia (t-all). her studies have uncovered critical insights into metabolic rewiring induced by genetic abnormalities, such as pten loss. she has also contributed to elucidating Oncologia the molecular blueprints of thymopoiesis and enhancer activation in tcr development. her recent work as a senior researcher has focused on the intersection of metabolism and oncogenesis, driving innovative therapeutic strategies for blood cancers.

🏆 Accolades and recognition

Melania’s contributions have been widely recognized in the scientific community. with an h-index of 19 and over 2,800 citations, her work has significantly impacted Oncologia cancer biology. she has been the last and corresponding author on prestigious publications, showcasing her leadership in collaborative research. her groundbreaking findings have been published in high-impact journals like blood advances, leukemia, and j experimental medicine, further establishing her as a thought leader in oncology research.

🌟 Impact and influence

Through her pioneering research, melania has advanced the understanding of key biological pathways in leukemia, offering new avenues for therapeutic Oncologia interventions. her work on age-related clinical features of pten abnormalities in t-all and molecular mechanisms of tcr enhancer activation has provided valuable frameworks for clinical applications. as a mentor, she has inspired the next generation of researchers, fostering a culture of innovation and collaboration.

🌍 Legacy and future contributions

Melania’s legacy is deeply rooted in her commitment to translational oncology, where she bridges the gap between fundamental research and clinical applications. looking ahead, she aims to expand her research into metabolic dependencies in cancer, paving the way for precision medicine approaches. her dedication to unraveling complex biological systems continues to shape the field of cancer research, ensuring lasting contributions to scientific progress and patient care.

Notable Publications

Title: Tell me who you go with and I'll tell you who you are
Author: M. Tesio
Journal: HemaSphere, 2024, 8(1), e36

Title: Editorial: Tyrosine kinases and phosphatases in T-cell malignancies
Author: M. Tesio
Journal: Frontiers in Oncology, 2024, 14, 1372133

Title: Sunscreen to Protect the Marrow
Author: M. Tesio
Journal: HemaSphere, 2023, 7(9), pp. E941

Title: Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
Author: M. Tesio
Journal: HemaSphere, 2023, 7(2), pp. E827

Title: Reporting From the First EHA Research Conference: Exciting Science With Panoramic Views
Author: M. Tesio
Journal: HemaSphere, 2023, 7(1), pp. E816